[go: up one dir, main page]

WO2004058329A3 - Ester combination local anesthetic - Google Patents

Ester combination local anesthetic Download PDF

Info

Publication number
WO2004058329A3
WO2004058329A3 PCT/US2003/041219 US0341219W WO2004058329A3 WO 2004058329 A3 WO2004058329 A3 WO 2004058329A3 US 0341219 W US0341219 W US 0341219W WO 2004058329 A3 WO2004058329 A3 WO 2004058329A3
Authority
WO
WIPO (PCT)
Prior art keywords
provides
ester
present
local anesthetic
ester combination
Prior art date
Application number
PCT/US2003/041219
Other languages
French (fr)
Other versions
WO2004058329A2 (en
Inventor
Steven L Shafer
Original Assignee
Univ Leland Stanford Junior
Steven L Shafer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior, Steven L Shafer filed Critical Univ Leland Stanford Junior
Priority to EP03800157A priority Critical patent/EP1572218A4/en
Priority to CA002507511A priority patent/CA2507511A1/en
Priority to MXPA05006771A priority patent/MXPA05006771A/en
Priority to AU2003299885A priority patent/AU2003299885A1/en
Priority to JP2004564039A priority patent/JP2006513224A/en
Priority to BR0317519-7A priority patent/BR0317519A/en
Publication of WO2004058329A2 publication Critical patent/WO2004058329A2/en
Publication of WO2004058329A3 publication Critical patent/WO2004058329A3/en
Priority to NO20053203A priority patent/NO20053203L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides compositions and methods for improved local anesthesia and/or analgesia, in which onset of action is rapid, the risk of toxicity is low, and the effect is sustained. More particularly, the present invention provides a combination of at least two ester anesthetics for administration to a subject, where at least one ester anesthetic provides a rapid onset of action and at least one ester anesthetic provides sustained activity. The compositions of the present invention are useful for the production of analgesia and/or anesthesia and are particularly useful for the prophylaxis and/or treatment of pain.
PCT/US2003/041219 2002-12-20 2003-12-18 Ester combination local anesthetic WO2004058329A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP03800157A EP1572218A4 (en) 2002-12-20 2003-12-18 LOCAL ANESTHESIC BASED ON AN ESTER COMBINATION
CA002507511A CA2507511A1 (en) 2002-12-20 2003-12-18 Ester combination local anesthetic
MXPA05006771A MXPA05006771A (en) 2002-12-20 2003-12-18 Ester combination local anesthetic.
AU2003299885A AU2003299885A1 (en) 2002-12-20 2003-12-18 Ester combination local anesthetic
JP2004564039A JP2006513224A (en) 2002-12-20 2003-12-18 Ester local anesthetic combinations
BR0317519-7A BR0317519A (en) 2002-12-20 2003-12-18 Pharmaceutical composition for local anesthesia and its use
NO20053203A NO20053203L (en) 2002-12-20 2005-06-30 Combination of local ester anesthetics.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32731002A 2002-12-20 2002-12-20
US10/327,310 2002-12-20

Publications (2)

Publication Number Publication Date
WO2004058329A2 WO2004058329A2 (en) 2004-07-15
WO2004058329A3 true WO2004058329A3 (en) 2004-12-29

Family

ID=32680753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/041219 WO2004058329A2 (en) 2002-12-20 2003-12-18 Ester combination local anesthetic

Country Status (10)

Country Link
EP (1) EP1572218A4 (en)
JP (1) JP2006513224A (en)
KR (1) KR20050085736A (en)
CN (1) CN1729004A (en)
AU (1) AU2003299885A1 (en)
BR (1) BR0317519A (en)
CA (1) CA2507511A1 (en)
MX (1) MXPA05006771A (en)
NO (1) NO20053203L (en)
WO (1) WO2004058329A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062836A1 (en) * 2004-09-21 2006-03-23 Carter Stephen G Methods of device-assisted drug delivery
CA2656966C (en) 2005-03-15 2014-06-10 Animal Ethics Pty Ltd A topical analgesic composition
ITMI20051633A1 (en) * 2005-09-06 2007-03-07 Sint Sa NEW USE OF A COMPOSITION INCLUDING CHOROPROCAINE HCL NEW COMPOSITION INCLUDING CHLOROPROCAINE HCL AND METHOD FOR ITS MANUFACTURING
US20100056575A1 (en) * 2006-07-19 2010-03-04 Jenkins Thomas E Anesthetic Compounds
US20080220062A1 (en) * 2006-10-23 2008-09-11 Psivida, Inc. Sustained release of agents for localized pain management
WO2009091546A1 (en) * 2008-01-18 2009-07-23 Pharmacofore, Inc. Anesthetic compounds
ITMI20122120A1 (en) * 2012-12-12 2014-06-13 Sint Sa PHARMACEUTICAL COMPOSITION BASED ON CHLOROPROCAIN FOR REPEATED INTRATECAL ADMINISTRATION
ITCR20130004A1 (en) * 2013-02-05 2014-08-06 Vincenzo Vigna SALVAVITA DRUG
US10117847B2 (en) 2015-12-04 2018-11-06 Ventis Pharma Extended duration local anesthetic formulation
DE102016215037B4 (en) 2016-08-11 2024-10-24 Lamello Ag spring device and connecting device
JOP20200010A1 (en) * 2017-09-15 2022-10-30 Sintetica S A Topical formulations of chloroprocaine and methods of use
WO2019226599A1 (en) * 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
JP6886551B1 (en) * 2020-11-06 2021-06-16 医療法人祥和会 Local anesthetic for dentistry

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
CA2388828A1 (en) * 1999-10-22 2001-06-14 Transdermatech, Inc. Topical anesthetic formulation
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US20020006435A1 (en) * 2000-01-27 2002-01-17 Samuels Paul J. Transdermal anesthetic and vasodilator composition and methods for topical administration

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1572218A4 *

Also Published As

Publication number Publication date
WO2004058329A2 (en) 2004-07-15
EP1572218A2 (en) 2005-09-14
CA2507511A1 (en) 2004-07-15
MXPA05006771A (en) 2005-09-08
BR0317519A (en) 2005-11-16
KR20050085736A (en) 2005-08-29
AU2003299885A1 (en) 2004-07-22
NO20053203D0 (en) 2005-06-30
NO20053203L (en) 2005-09-19
CN1729004A (en) 2006-02-01
EP1572218A4 (en) 2007-05-16
JP2006513224A (en) 2006-04-20

Similar Documents

Publication Publication Date Title
MXPA04005790A (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase.
WO2004058329A3 (en) Ester combination local anesthetic
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
TW200633695A (en) Methods for purifying trans-(-)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
EP1426375A3 (en) Analgesic spiroindole derivatives
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
WO2002038171A3 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
HK1065941A1 (en) Use of a nicotinic acid alkyl ester containing an alkyl chain from 8 to 22 carbon atoms for the preparation of a medicament for increasing leptin levels in a subject
WO2004043341A3 (en) Treatment for hemorrhagic shock
DE602004011394D1 (en) Thiazolderivate
MX2007012794A (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin.
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
EP1177791A3 (en) Use of glycogen phosphorylase inhibitors to inhibit tumor growth
UA92498C2 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
HK1081861A1 (en) New synergistic combination comprising roflumilast and formoterol
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
HK1081862A1 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
MXPA05008711A (en) Use of r-10-hydroxy-10, 11-dihydro-carbamazepine in neuropathic pain.
UA97961C2 (en) Therapy and/or amelioration method for disseminated intravascular coagulation
WO2002065984A3 (en) Compounds having retinoid-like activity
IL175357A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 168743

Country of ref document: IL

Ref document number: 2003299885

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2507511

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003800157

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020057011263

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/006771

Country of ref document: MX

Ref document number: 2004564039

Country of ref document: JP

Ref document number: 20038A70196

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057011263

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003800157

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0317519

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2003800157

Country of ref document: EP